Dear Reader, I (Dr. Eifrig) recently sat down for an interview in which I broke down one of the most lucrative tipping points in the world of investing... The inflection moment when a fatal disease transforms into a chronic, manageable condition. I demonstrated how Eli Lilly leveraged this tipping point in diabetes and consequently soared nearly 180-fold. I showed how Vertex Pharmaceuticals, Gilead Sciences, Amgen, and Merck all harnessed this unique catalyst to deliver massive returns for their shareholders as well. And I capped it all off by pointing out how I believe Novo Nordisk is set to make history repeat again this October when it publishes the results of its four-year investigation into the impact of its GLP-1 drug semaglutide – which you may know as Ozempic or Wegovy – on Alzheimer's. I believe Novo Nordisk has a strong chance of turning this cruel, dehumanizing condition into something that can be managed on a long-term basis. And if the results of this study are clinically significant, they could cause shares of Novo to DOUBLE within the next two years. If you're interested in buying its stock, I recommend that you get into position now. The ticker symbol for Novo Nordisk is NVO. Don't buy it for more than $75 a share. That said, this story is far bigger than Novo Nordisk... We're talking about a sea-change that could overhaul the medical landscape. GLP-1 drugs hold the potential to treat not only Alzheimer's, obesity, and type 2 diabetes, but over 200 additional diseases and health conditions. Everything from anxiety and depression to heart disease and 10 forms of cancer. If you want to profit from what the Guardian calls "the most scientifically exciting and commercially lucrative area of healthcare," you have to look into one of my favorite ways to play this space. This company has a whopping 11 GLP-1 drugs in the pipeline, and it's rapidly capturing market share. I've recommended this stock twice before, giving my readers the chance to book 143% and 133% gains, respectively. Now I'm tripling down on this firm, and I'm inviting you to check it out for yourself. But if you want to find out the name and ticker symbol of the GLP-1 stock I'm now targeting, you have to access my presentation by tomorrow. It's going offline tomorrow at midnight. If you don't move now, you may miss your chance. Click here to learn more. Here's to our health, wealth, and a great retirement, Dr. David Eifrig, MD, MBA
Senior Partner, Stansberry Research
CEO, MarketWise | 
No comments:
Post a Comment
Keep a civil tongue.